Peter A. Riedell, MD | Authors


Exploring a Time-to-Relapse Analysis for Rituximab and Transplant in MCL

July 24, 2021

Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.